Molecular evidence for Plasmodium falciparum resistance to sulfadoxine–pyrimethamine but absence of K13 mutations in Mangaluru, Southwestern India

Jakob Wedam, Costanza Tacoli, Prabhanjan P. Gai, Konrad Siegert, Suyamindra S. Kulkarni, Rashmi Rasalkar, Archith Boloor, Animesh Jain, Chakrapani Mahabala, Shantaram Baliga, Damodara Shenoy, Rajeshwari Devi, Pramod Gai, Frank P. Mockenhaupt

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

In most of India, sulfadoxine–pyrimethamine (SP) plus artesunate serves as first-line treatment for uncomplicated falciparum malaria. In 112 clinical Plasmodium falciparum isolates from Mangaluru, southwestern India, we sequenced molecular markers associated with resistance to SP, lumefantrine, and artemisinin (pfdhfr, pfdhps, pfmdr1, and K13). The pfdhfr double mutation 59R-108N combined with the dhps 437G mutation occurred in 39.3% and the pfdhfr double mutation plus the pfdhps double mutation 437G-540E in additional 24.1%. As for pfmdr1, the allele combination N86-184F-D1246 dominated (98.2%). K13 variants were absent. No evidence for artemisinin resistance was seen. However, the antifolate resistance alleles compromise the current first-line antimalarial sulfadoxine–pyrimethamine plus artesunate, which may facilitate the emergence of artemisinin resistance. Artemether–lumefantrine, introduced in northeastern parts of the country, in the study area faces the predominant pfmdr1 NFD genotype, known to impair lumefantrine efficacy. Further monitoring of resistance alleles and treatment trials on alternative artemisinin-based combination therapies are required.

Original languageEnglish
Pages (from-to)1508-1510
Number of pages3
JournalAmerican Journal of Tropical Medicine and Hygiene
Volume99
Issue number6
DOIs
Publication statusPublished - 01-01-2018

Fingerprint

Plasmodium falciparum
India
Mutation
Alleles
Folic Acid Antagonists
Falciparum Malaria
Antimalarials
Genotype
artemisinine
artesunate
lumefantrine
Therapeutics

All Science Journal Classification (ASJC) codes

  • Parasitology
  • Infectious Diseases
  • Virology

Cite this

Wedam, Jakob ; Tacoli, Costanza ; Gai, Prabhanjan P. ; Siegert, Konrad ; Kulkarni, Suyamindra S. ; Rasalkar, Rashmi ; Boloor, Archith ; Jain, Animesh ; Mahabala, Chakrapani ; Baliga, Shantaram ; Shenoy, Damodara ; Devi, Rajeshwari ; Gai, Pramod ; Mockenhaupt, Frank P. / Molecular evidence for Plasmodium falciparum resistance to sulfadoxine–pyrimethamine but absence of K13 mutations in Mangaluru, Southwestern India. In: American Journal of Tropical Medicine and Hygiene. 2018 ; Vol. 99, No. 6. pp. 1508-1510.
@article{ca5917902b3a48b19415101ad428b2e7,
title = "Molecular evidence for Plasmodium falciparum resistance to sulfadoxine–pyrimethamine but absence of K13 mutations in Mangaluru, Southwestern India",
abstract = "In most of India, sulfadoxine–pyrimethamine (SP) plus artesunate serves as first-line treatment for uncomplicated falciparum malaria. In 112 clinical Plasmodium falciparum isolates from Mangaluru, southwestern India, we sequenced molecular markers associated with resistance to SP, lumefantrine, and artemisinin (pfdhfr, pfdhps, pfmdr1, and K13). The pfdhfr double mutation 59R-108N combined with the dhps 437G mutation occurred in 39.3{\%} and the pfdhfr double mutation plus the pfdhps double mutation 437G-540E in additional 24.1{\%}. As for pfmdr1, the allele combination N86-184F-D1246 dominated (98.2{\%}). K13 variants were absent. No evidence for artemisinin resistance was seen. However, the antifolate resistance alleles compromise the current first-line antimalarial sulfadoxine–pyrimethamine plus artesunate, which may facilitate the emergence of artemisinin resistance. Artemether–lumefantrine, introduced in northeastern parts of the country, in the study area faces the predominant pfmdr1 NFD genotype, known to impair lumefantrine efficacy. Further monitoring of resistance alleles and treatment trials on alternative artemisinin-based combination therapies are required.",
author = "Jakob Wedam and Costanza Tacoli and Gai, {Prabhanjan P.} and Konrad Siegert and Kulkarni, {Suyamindra S.} and Rashmi Rasalkar and Archith Boloor and Animesh Jain and Chakrapani Mahabala and Shantaram Baliga and Damodara Shenoy and Rajeshwari Devi and Pramod Gai and Mockenhaupt, {Frank P.}",
year = "2018",
month = "1",
day = "1",
doi = "10.4269/ajtmh.18-0549",
language = "English",
volume = "99",
pages = "1508--1510",
journal = "American Journal of Tropical Medicine and Hygiene",
issn = "0002-9637",
publisher = "American Society of Tropical Medicine and Hygiene",
number = "6",

}

Molecular evidence for Plasmodium falciparum resistance to sulfadoxine–pyrimethamine but absence of K13 mutations in Mangaluru, Southwestern India. / Wedam, Jakob; Tacoli, Costanza; Gai, Prabhanjan P.; Siegert, Konrad; Kulkarni, Suyamindra S.; Rasalkar, Rashmi; Boloor, Archith; Jain, Animesh; Mahabala, Chakrapani; Baliga, Shantaram; Shenoy, Damodara; Devi, Rajeshwari; Gai, Pramod; Mockenhaupt, Frank P.

In: American Journal of Tropical Medicine and Hygiene, Vol. 99, No. 6, 01.01.2018, p. 1508-1510.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Molecular evidence for Plasmodium falciparum resistance to sulfadoxine–pyrimethamine but absence of K13 mutations in Mangaluru, Southwestern India

AU - Wedam, Jakob

AU - Tacoli, Costanza

AU - Gai, Prabhanjan P.

AU - Siegert, Konrad

AU - Kulkarni, Suyamindra S.

AU - Rasalkar, Rashmi

AU - Boloor, Archith

AU - Jain, Animesh

AU - Mahabala, Chakrapani

AU - Baliga, Shantaram

AU - Shenoy, Damodara

AU - Devi, Rajeshwari

AU - Gai, Pramod

AU - Mockenhaupt, Frank P.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - In most of India, sulfadoxine–pyrimethamine (SP) plus artesunate serves as first-line treatment for uncomplicated falciparum malaria. In 112 clinical Plasmodium falciparum isolates from Mangaluru, southwestern India, we sequenced molecular markers associated with resistance to SP, lumefantrine, and artemisinin (pfdhfr, pfdhps, pfmdr1, and K13). The pfdhfr double mutation 59R-108N combined with the dhps 437G mutation occurred in 39.3% and the pfdhfr double mutation plus the pfdhps double mutation 437G-540E in additional 24.1%. As for pfmdr1, the allele combination N86-184F-D1246 dominated (98.2%). K13 variants were absent. No evidence for artemisinin resistance was seen. However, the antifolate resistance alleles compromise the current first-line antimalarial sulfadoxine–pyrimethamine plus artesunate, which may facilitate the emergence of artemisinin resistance. Artemether–lumefantrine, introduced in northeastern parts of the country, in the study area faces the predominant pfmdr1 NFD genotype, known to impair lumefantrine efficacy. Further monitoring of resistance alleles and treatment trials on alternative artemisinin-based combination therapies are required.

AB - In most of India, sulfadoxine–pyrimethamine (SP) plus artesunate serves as first-line treatment for uncomplicated falciparum malaria. In 112 clinical Plasmodium falciparum isolates from Mangaluru, southwestern India, we sequenced molecular markers associated with resistance to SP, lumefantrine, and artemisinin (pfdhfr, pfdhps, pfmdr1, and K13). The pfdhfr double mutation 59R-108N combined with the dhps 437G mutation occurred in 39.3% and the pfdhfr double mutation plus the pfdhps double mutation 437G-540E in additional 24.1%. As for pfmdr1, the allele combination N86-184F-D1246 dominated (98.2%). K13 variants were absent. No evidence for artemisinin resistance was seen. However, the antifolate resistance alleles compromise the current first-line antimalarial sulfadoxine–pyrimethamine plus artesunate, which may facilitate the emergence of artemisinin resistance. Artemether–lumefantrine, introduced in northeastern parts of the country, in the study area faces the predominant pfmdr1 NFD genotype, known to impair lumefantrine efficacy. Further monitoring of resistance alleles and treatment trials on alternative artemisinin-based combination therapies are required.

UR - http://www.scopus.com/inward/record.url?scp=85058167927&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058167927&partnerID=8YFLogxK

U2 - 10.4269/ajtmh.18-0549

DO - 10.4269/ajtmh.18-0549

M3 - Article

VL - 99

SP - 1508

EP - 1510

JO - American Journal of Tropical Medicine and Hygiene

JF - American Journal of Tropical Medicine and Hygiene

SN - 0002-9637

IS - 6

ER -